From Self-sufficiency
Jump to: navigation, search
Systematic (IUPAC) name
Clinical data
Routes of
Legal status
Legal status
  • Uncontrolled
CAS Number 169758-66-1
ATC code none
PubChem CID 3055171
Chemical data
Formula C18H23FN2O2
Molar mass 318.174 g/mol[[Script error: No such module "String".]]
Script error: No such module "collapsible list".
Script error: No such module "TemplatePar".Expression error: Unexpected < operator.

Robalzotan (NAD-299, AZD-7371) is a selective antagonist at the 5-HT1A receptor.[1] It was shown to completely reverse the autoreceptor-mediated inhibition of serotonin release induced by the administration of selective serotonin reuptake inhibitors like citalopram in rodent studies.[2] It was subsequently investigated by AstraZeneca as a potential antidepressant but like many other 5-HT1A agonists was discontinued.[3] Later on it was researched for other indications such as irritable bowel syndrome but was dropped once again.[4]

See also


Cite error: Invalid <references> tag; parameter "group" is allowed only.

Use <references />, or <references group="..." />

  1. Jerning E, Svantesson GT, Mohell N. (1998). "Receptor binding characteristics of [3H]NAD-299, a new selective 5-HT1A receptor antagonist". Eur J Pharmacol. 360 (2-3): 219–225. doi:10.1016/S0014-2999(98)00667-0. PMID 9851589. 
  2. Arborelius L, Wallsten C, Ahlenius S, Svensson TH. (1999). "The 5-HT(1A) receptor antagonist robalzotan completely reverses citalopram-induced inhibition of serotonergic cell firing". Eur J Pharmacol. 382 (2): 133–138. doi:10.1016/S0014-2999(99)00592-0. PMID 10528148. 
  3. Mucke HA. (2000). "Robalzotan AstraZeneca". Curr Opin Investig Drugs. 1 (2): 236–240. PMID 11249580. 
  4. Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.